- Page 1 and 2: Annals of Oncology Official Journal
- Page 3 and 4: Annals of Oncology Official Journal
- Page 5 and 6: The European Society for Medical On
- Page 7: Gastrointestinal tumours, non-color
- Page 11 and 12: abstracts proteins, and classified
- Page 13 and 14: abstracts Annals of Oncology 12P Re
- Page 15 and 16: abstracts SOX2, NANOG, OCT4, and E2
- Page 17 and 18: abstracts were checked on the mRNA
- Page 19 and 20: abstracts has been shown to increas
- Page 21 and 22: abstracts 43P Oncoguide system - A
- Page 23 and 24: abstracts Results: Using IHC, we de
- Page 25 and 26: abstracts Legal entity responsible
- Page 27 and 28: abstracts Annals of Oncology Astell
- Page 29 and 30: abstracts Annals of Oncology 66P Th
- Page 31 and 32: abstracts respectively. Giemsa stai
- Page 33 and 34: abstracts mutation in the splice si
- Page 35 and 36: abstracts 86P Serum interleukin-6 a
- Page 37 and 38: abstracts (Idylla, Biocartis) and M
- Page 39 and 40: abstracts Annals of Oncology Conclu
- Page 41 and 42: abstracts Legal entity responsible
- Page 43 and 44: abstracts 113P Characteristics of h
- Page 45 and 46: abstracts a strong need of reliable
- Page 47 and 48: abstracts Results: Of 105 received
- Page 49 and 50: abstracts 135P ACE and CXCL10 as pr
- Page 51 and 52: abstracts 141P Identification of ba
- Page 53 and 54: abstracts Annals of Oncology 146O O
- Page 55 and 56: abstracts #of positive LN Micromets
- Page 57 and 58: abstracts Conclusions: Our study sh
- Page 59 and 60:
abstracts 165P Tumor lymphocyte inf
- Page 61 and 62:
abstracts Annals of Oncology the mo
- Page 63 and 64:
abstracts prognostic and predictive
- Page 65 and 66:
abstracts Annals of Oncology 21% of
- Page 67 and 68:
abstracts Conclusions: The present
- Page 69 and 70:
abstracts Conclusions: In our study
- Page 71 and 72:
abstracts 205P Individual approach
- Page 73 and 74:
abstracts event (AE) profile in the
- Page 75 and 76:
abstracts Funding: Zhejiang Cancer
- Page 77 and 78:
Annals of Oncology 27 (Supplement 6
- Page 79 and 80:
abstracts pts (70%) and CT for 159
- Page 81 and 82:
abstracts Methods: Eighty-five pati
- Page 83 and 84:
abstracts LM is a full-time employe
- Page 85 and 86:
abstracts unknown. In 14 patients M
- Page 87 and 88:
abstracts Conclusions: Patients wit
- Page 89 and 90:
abstracts towards an association wi
- Page 91 and 92:
abstracts Annals of Oncology Table:
- Page 93 and 94:
abstracts Conclusions: In our study
- Page 95 and 96:
abstracts Annals of Oncology 275P T
- Page 97 and 98:
abstracts adverse events and their
- Page 99 and 100:
abstracts Annals of Oncology 286P F
- Page 101 and 102:
abstracts (dNLR) is easily accessib
- Page 103 and 104:
abstracts Annals of Oncology 297P H
- Page 105 and 106:
abstracts more advanced disease in
- Page 107 and 108:
abstracts Annals of Oncology 311TiP
- Page 109 and 110:
Annals of Oncology 27 (Supplement 6
- Page 111 and 112:
abstracts on the high resolution tr
- Page 113 and 114:
abstracts 325O Routine molecular su
- Page 115 and 116:
abstracts Results: Twenty patients
- Page 117 and 118:
abstracts temozolomide and radiothe
- Page 119 and 120:
abstracts Annals of Oncology 346P A
- Page 121 and 122:
abstracts was recorded monopolarly
- Page 123 and 124:
Annals of Oncology 27 (Supplement 6
- Page 125 and 126:
abstracts 363PD Molecular imaging o
- Page 127 and 128:
abstracts Results: Our results indi
- Page 129 and 130:
abstracts Disclosure: Y-K. Kang: I
- Page 131 and 132:
abstracts TAK-228 PK was evaluated
- Page 133 and 134:
abstracts Results: In vitro, inhibi
- Page 135 and 136:
abstracts Annals of Oncology Table:
- Page 137 and 138:
abstracts Conclusions: MTD for CRLX
- Page 139 and 140:
abstracts Conclusions: The nanopart
- Page 141 and 142:
abstracts Annals of Oncology - 369)
- Page 143 and 144:
abstracts Disclosure: I. Kiss: Has
- Page 145 and 146:
Annals of Oncology 27 (Supplement 6
- Page 147 and 148:
abstracts Clinical trial identifica
- Page 149 and 150:
abstracts Therapy (PRRT) (3; 7%). T
- Page 151 and 152:
abstracts Funding: University of Wa
- Page 153 and 154:
abstracts 438P Efficacy of lanreoti
- Page 155 and 156:
abstracts 443P Prognostic impact of
- Page 157 and 158:
abstracts Disclosure: Y. Takiguchi:
- Page 159 and 160:
abstracts Annals of Oncology 455O E
- Page 161 and 162:
abstracts Annals of Oncology 460O P
- Page 163 and 164:
abstracts analysis and aimed to ide
- Page 165 and 166:
abstracts 467PD Preoperative chemor
- Page 167 and 168:
abstracts Annals of Oncology 472P A
- Page 169 and 170:
abstracts Annals of Oncology KRAS w
- Page 171 and 172:
abstracts committees or principal i
- Page 173 and 174:
abstracts Disclosure: D. Malka, J.
- Page 175 and 176:
abstracts Conclusions: Both treatme
- Page 177 and 178:
abstracts Annals of Oncology 23m. R
- Page 179 and 180:
abstracts metastases were predictiv
- Page 181 and 182:
abstracts 510P Phase II study of th
- Page 183 and 184:
abstracts 515P RECOURSE trial: Perf
- Page 185 and 186:
abstracts paracortex, and the medul
- Page 187 and 188:
abstracts Annals of Oncology 526P P
- Page 189 and 190:
abstracts Annals of Oncology Table:
- Page 191 and 192:
abstracts low SII and NLR,sufficien
- Page 193 and 194:
abstracts Methods: All patients wer
- Page 195 and 196:
abstracts FOLFOX after first progre
- Page 197 and 198:
abstracts and the United States. Ad
- Page 199 and 200:
abstracts Results: Mean age of Grou
- Page 201 and 202:
abstracts Annals of Oncology Table:
- Page 203 and 204:
abstracts Results: Expression level
- Page 205 and 206:
abstracts multicenter data.The aim
- Page 207 and 208:
abstracts Annals of Oncology questi
- Page 209 and 210:
abstracts Annals of Oncology 589P I
- Page 211 and 212:
abstracts were randomized between m
- Page 213 and 214:
abstracts or more lines of chemothe
- Page 215 and 216:
abstracts 607TiP TransSCOT - transl
- Page 217 and 218:
abstracts Annals of Oncology 613O G
- Page 219 and 220:
abstracts Annals of Oncology 617PD
- Page 221 and 222:
abstracts Methods: Pts in Arm A rec
- Page 223 and 224:
abstracts 627P Histopathological re
- Page 225 and 226:
abstracts 633P Efficacy and safety
- Page 227 and 228:
abstracts 639P The final results of
- Page 229 and 230:
abstracts FP-19.4%). The overall in
- Page 231 and 232:
abstracts 652P Prognostic implicati
- Page 233 and 234:
abstracts LN was even higher among
- Page 235 and 236:
abstracts Methods: Nab-Paclitaxel a
- Page 237 and 238:
abstracts 674P Dynamics of the HER2
- Page 239 and 240:
abstracts Annals of Oncology 679P G
- Page 241 and 242:
abstracts Annals of Oncology 684P N
- Page 243 and 244:
abstracts 690P Efficacy of neoadjuv
- Page 245 and 246:
abstracts Annals of Oncology 696P E
- Page 247 and 248:
abstracts is emerging as a potentia
- Page 249 and 250:
abstracts clinical effect of the tw
- Page 251 and 252:
abstracts declare.M. Ebert: This in
- Page 253 and 254:
abstracts 719O First evidence of si
- Page 255 and 256:
abstracts and CNCSIS.M. Chadjaa: Is
- Page 257 and 258:
abstracts were followed up to 29.5
- Page 259 and 260:
abstracts Annals of Oncology 734P N
- Page 261 and 262:
abstracts Results: With 2051 men in
- Page 263 and 264:
abstracts Disclosure: O. Caffo: Hon
- Page 265 and 266:
abstracts Clinical trial identifica
- Page 267 and 268:
abstracts 752P Radium-223 re-treatm
- Page 269 and 270:
abstracts hypothesized the DDRD pos
- Page 271 and 272:
abstracts including treatment effic
- Page 273 and 274:
abstracts receptor blocker, improve
- Page 275 and 276:
Annals of Oncology 27 (Supplement 6
- Page 277 and 278:
abstracts reaction (29 pts [22.5%])
- Page 279 and 280:
abstracts 782PD IMvigor210: updated
- Page 281 and 282:
abstracts Annals of Oncology of cli
- Page 283 and 284:
abstracts patients with MIUC as pro
- Page 285 and 286:
abstracts Annals of Oncology 797P N
- Page 287 and 288:
abstracts demonstrated modest activ
- Page 289 and 290:
abstracts Results: Eleven of 34 eva
- Page 291 and 292:
abstracts Legal entity responsible
- Page 293 and 294:
abstracts Disclosure: N. Tannir: Ho
- Page 295 and 296:
abstracts another anti-VEGF/anti-mT
- Page 297 and 298:
abstracts 831P Outcome of patients
- Page 299 and 300:
abstracts 837P Long-term changes in
- Page 301 and 302:
abstracts 843TiP Surf: Open label,
- Page 303 and 304:
abstracts and assessment. Surveilla
- Page 305 and 306:
Annals of Oncology 27 (Supplement 6
- Page 307 and 308:
abstracts to increase response rate
- Page 309 and 310:
abstracts 865P Hypersensitivity rea
- Page 311 and 312:
abstracts higher VEGF production th
- Page 313 and 314:
abstracts 877P Treatment patterns a
- Page 315 and 316:
abstracts Annals of Oncology events
- Page 317 and 318:
abstracts Results: Univariate analy
- Page 319 and 320:
abstracts 896P Overxpression of HER
- Page 321 and 322:
abstracts 903TiP Preoperative olapa
- Page 323 and 324:
abstracts Annals of Oncology 908O H
- Page 325 and 326:
abstracts (p = 0.007); and higher F
- Page 327 and 328:
abstracts Methods: FFPE samples fro
- Page 329 and 330:
abstracts IP was 17 days. All patie
- Page 331 and 332:
abstracts Methods: Gonadal function
- Page 333 and 334:
abstracts repeated 28-day cycles, w
- Page 335 and 336:
abstracts current or history of cen
- Page 337 and 338:
Annals of Oncology 27 (Supplement 6
- Page 339 and 340:
abstracts PET-CT surveillance strat
- Page 341 and 342:
abstracts Annals of Oncology 958P T
- Page 343 and 344:
abstracts Sharpe & Dohme; and recei
- Page 345 and 346:
abstracts Results: Among the first
- Page 347 and 348:
abstracts frequently disrupted duri
- Page 349 and 350:
abstracts haematological (8.9%), ga
- Page 351 and 352:
abstracts Annals of Oncology (z = 1
- Page 353 and 354:
abstracts tyrosine kinase activity.
- Page 355 and 356:
abstracts Results: Between April 20
- Page 357 and 358:
abstracts mandibular glands. These
- Page 359 and 360:
abstracts is a randomized, open-lab
- Page 361 and 362:
abstracts Legal entity responsible
- Page 363 and 364:
abstracts Tx discontinuation (TTD,
- Page 365 and 366:
abstracts Annals of Oncology use po
- Page 367 and 368:
abstracts 1044P Incremental cost-ef
- Page 369 and 370:
abstracts Annals of Oncology AZD915
- Page 371 and 372:
abstracts 1053PD A first-in-human (
- Page 373 and 374:
abstracts 1060P Prevalence of PD-L1
- Page 375 and 376:
abstracts 1065P T cell responses in
- Page 377 and 378:
abstracts Annals of Oncology weeks
- Page 379 and 380:
abstracts Methods: We reviewed all
- Page 381 and 382:
abstracts with matching tumour cell
- Page 383 and 384:
abstracts 5.9 ± 2.3% central memor
- Page 385 and 386:
abstracts having difficulties recov
- Page 387 and 388:
abstracts 1103TiP MEDIOLA: A phase
- Page 389 and 390:
abstracts Annals of Oncology 1111O
- Page 391 and 392:
abstracts PRs), TNBC (n = 3; 2 SDs)
- Page 393 and 394:
abstracts Results: Twenty-four pts
- Page 395 and 396:
abstracts Annals of Oncology Disclo
- Page 397 and 398:
abstracts 1126P Slow natural histor
- Page 399 and 400:
abstracts knowledge gap regarding t
- Page 401 and 402:
abstracts 1137P Health-related qual
- Page 403 and 404:
abstracts Novartis. J.J. Grob: Cons
- Page 405 and 406:
abstracts 1146P Tumor response from
- Page 407 and 408:
abstracts 1152P Evaluation of the p
- Page 409 and 410:
abstracts 1157TiP Phase Ib study of
- Page 411 and 412:
abstracts patients in many indicati
- Page 413 and 414:
abstracts cytokeratin (CK) in lavag
- Page 415 and 416:
abstracts Annals of Oncology 1176P
- Page 417 and 418:
abstracts Annals of Oncology 1181P
- Page 419 and 420:
abstracts 1157 (19%) were operated
- Page 421 and 422:
abstracts 1189P Functional profilin
- Page 423 and 424:
abstracts edition) NSCLC was evalua
- Page 425 and 426:
Annals of Oncology 27 (Supplement 6
- Page 427 and 428:
abstracts Annals of Oncology Result
- Page 429 and 430:
abstracts stock and other ownership
- Page 431 and 432:
abstracts Annals of Oncology 1214PD
- Page 433 and 434:
abstracts Legal entity responsible
- Page 435 and 436:
abstracts Annals of Oncology 1221P
- Page 437 and 438:
abstracts Conclusions: Our findings
- Page 439 and 440:
abstracts 1231P Efficacy of first-g
- Page 441 and 442:
abstracts objective response rate (
- Page 443 and 444:
abstracts 1241P Afatinib efficacy a
- Page 445 and 446:
abstracts ACEA, Vertex, Aveo&Biodes
- Page 447 and 448:
abstracts Conclusions: For advanced
- Page 449 and 450:
abstracts Annals of Oncology 1260P
- Page 451 and 452:
abstracts aims to assess whether li
- Page 453 and 454:
abstracts Annals of Oncology 1271P
- Page 455 and 456:
abstracts Conclusions: NIN plus DOC
- Page 457 and 458:
abstracts Clinical trial identifica
- Page 459 and 460:
abstracts patients with c-Met+ tumo
- Page 461 and 462:
abstracts the Y1003 CBL ubiquitin l
- Page 463 and 464:
abstracts administered for a maximu
- Page 465 and 466:
abstracts Results: We identified 5
- Page 467 and 468:
abstracts 1311P End of life (EOL) c
- Page 469 and 470:
abstracts procedure. Prognostic & p
- Page 471 and 472:
Annals of Oncology 27 (Supplement 6
- Page 473 and 474:
abstracts (10%) respectively. Twelv
- Page 475 and 476:
abstracts Legal entity responsible
- Page 477 and 478:
abstracts Annals of Oncology ELISA
- Page 479 and 480:
abstracts 1352P Empowerment in adol
- Page 481 and 482:
abstracts 1358P Evaluation of burno
- Page 483 and 484:
Annals of Oncology 27 (Supplement 6
- Page 485 and 486:
abstracts identified by logistic re
- Page 487 and 488:
abstracts More than 50% consider AS
- Page 489 and 490:
abstracts Methods: A retrospective
- Page 491 and 492:
abstracts 1393P Capecitabine/oxalip
- Page 493 and 494:
abstracts Annals of Oncology 1397O
- Page 495 and 496:
abstracts Annals of Oncology Table:
- Page 497 and 498:
abstracts Conclusions: Pazopanib sh
- Page 499 and 500:
abstracts Legal entity responsible
- Page 501 and 502:
abstracts or metastatic STS (≥16
- Page 503 and 504:
abstracts 1425PD Clinical activity,
- Page 505 and 506:
abstracts 1430TiP STIMULI: A random
- Page 507 and 508:
abstracts 1435O Exploration of the
- Page 509 and 510:
abstracts Disclosure: K. Jordan: Co
- Page 511 and 512:
abstracts (24-120 hours after CDDP
- Page 513 and 514:
abstracts 1452P Risk model for clin
- Page 515 and 516:
abstracts study, the MASCC score wa
- Page 517 and 518:
abstracts 1464P Comparison of the s
- Page 519 and 520:
abstracts were affected by lung can
- Page 521 and 522:
abstracts 1476P Comparison of the u
- Page 523 and 524:
abstracts 1482P Concerns of young w
- Page 525 and 526:
abstracts Conclusions: In the absen
- Page 527 and 528:
abstracts Annals of Oncology Table:
- Page 529 and 530:
abstracts 1502P Insomnia prevalence
- Page 531 and 532:
Annals of Oncology 27 (Supplement 6
- Page 533 and 534:
abstracts Results: Univariate analy
- Page 535 and 536:
Annals of Oncology 27 (Supplement 6
- Page 537 and 538:
abstracts type of LC. This collecti
- Page 539 and 540:
abstracts 1531P Evaluation of the i
- Page 541 and 542:
abstracts 1538P Neutrophil-to-lymph
- Page 543 and 544:
abstracts Annals of Oncology Result
- Page 545 and 546:
abstracts 1551P Epithelial to mesen
- Page 547 and 548:
abstracts ClearCell FX system (Clea
- Page 549 and 550:
abstracts the cholesterol side chai
- Page 551 and 552:
abstracts Methods: We surveyed >300
- Page 553 and 554:
abstracts Results: In transduced ce
- Page 555 and 556:
abstracts 1584P Germline genetic ba
- Page 557 and 558:
abstracts Legal entity responsible
- Page 559 and 560:
abstracts Conclusions: Our findings
- Page 561 and 562:
drug index Annals Of Oncology 27 (S
- Page 563 and 564:
drug index Annals Of Oncology drug
- Page 565 and 566:
translational research index Annals
- Page 567 and 568:
translational research index Annals
- Page 569 and 570:
translational research index Annals